Scalper1 News
Biotech Endocyte (ECYT) got a couple of hefty price-target increases from analysts Tuesday in the wake of last week’s positive Vynfinit news, sending the stock up about 4% in morning trading on the stock market today, near 28.30. Wedbush analyst Gregory Wade lifted his target to 65 from 23, giving room for substantial upside even after Friday’s more than 100% intraday jump to a record high of 33.70. He estimates $430 million in peak annual sales Scalper1 News
Scalper1 News